From time to time we publish a full review of drugs that are available for the treatment of
common conditions. In this issue, the review is written by two of the leading authorities in the …

Benign prostatic hyperplasia (BPH) is the most common benign disease of the prostate
gland and is caused by benign hyperplasia of the smooth muscle cells and stromal cells in …

Muscarinic receptor antagonists (antimuscarinics) serve as the cornerstone in the
pharmacological management of overactive bladder (OAB) by relieving the symptoms of …

Objectives: To evaluate the efficacy, tolerability and safety of darifenacin, a once-daily M3
selective receptor antagonist (M3 SRA), in patients with overactive bladder (OAB). Methods …

Benign prostatic hyperplasia (BPH) and its associated is one of the most common diagnoses
seen by the urologist, with previous studies estimating greater than half of the men having at …

With the continued aging of the population, the incidence of conditions associated with
bladder control will continue to grow. In this article, we review the neurophysiology and …

The functions of the lower urinary tract, to store and periodically release urine, are
dependent on the activity of smooth and striated muscles in the bladder, urethra, and …

OBJECTIVES: Patients with neurogenic bladder dysfunction demonstrate an insufficient
treatment outcome under dosage-escalated monotherapy. With the objectives of continence …

Overactive bladder syndrome (OAB) is a symptomatic diagnosis based on the presence of
urgency, with or without urge incontinence, and usually accompanied by frequency and …

Small conductance, calcium‐activated potassium (SK) channels have an important role in
determining the excitability and contractility of urinary bladder smooth muscle. Here, the role …